TY - JOUR
T1 - Characterization of First-line Use of Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors in Metastatic Breast Cancer among Florida Health Care Systems.
AU - Mahtani, Reshma
N1 - e19347 Background: First-line treatment with a CDK4/6 inhibitor in combination with an aromatase inhibitor for HR+/HER2- postmenopausal metastatic breast cancer (mBC) is considered standard of care based on the compelling data across all landmark trials.
PY - 2020
Y1 - 2020
N2 - Reshma L. Mahtani , Luis E. Raez , Jessica Unzaga , Jorge J García , Krupa Paranjpe , Irene Arias , Aurelio Bartolome Castrellon
AB - Reshma L. Mahtani , Luis E. Raez , Jessica Unzaga , Jorge J García , Krupa Paranjpe , Irene Arias , Aurelio Bartolome Castrellon
UR - https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.e19347
M3 - Article
VL - 38
JO - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting
JF - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting
ER -